The gender-specific features of cardiovascular diseases (CVD) are actively being discussed which puts on the agenda the development of a differentiated approach to the treatment of cardiac diseases in men and women. Аim. To assess the gender-specific features of the antioxidant status and antioxidative activity of atorvastatin in patients with stable forms of coronary heart disease (CHD) and dyslipidemia (DLP). Material and methods. The study included 102 patients with stable forms of CHD divided into 2 groups according to sex and 40 healthy individuals. The generally accepted methods were used to determine plasma lipids, products of their peroxidation (diene conjugates, DC) and the products reacting with 2-thiobarbituric acid (TBA-RP), the antioxidant enzymes glutathione peroxidase (GP) and superoxide dismutase (SOD) in erythrocytes; the activity of the ceruloplasmin/transferrin antioxidant system (AOA AOS CP/TF) in blood plasma was measured by electron paramagnetic resonance and the final metabolites of nitric oxide with the use of the Griss reagent. The endothelial function was studied by ultrasound with the assessment of endothelium-dependent vasodilatation as described by D. Celermajer et al. (1992). All parameters were evaluated before and 6 months after the onset of the treatment. Results. The men with CHD, unlike women, underwent a reduction of AOA AOS CP/TF by 10%, SOD by 12% and GP by 19% (p<0.05) as well as excessive accumulation of DC up to 9% and TBA-RP to 11% (p<0.05). The homocysteine level in men, was 1.5 times higher (p=0.01), and that of final nitric oxide metabolites 12% lower (p=0.03) than in women. Atorvastatin administered for 6 months as a component of combined cardiac therapy more significantly increased the activity of AOS CP/TF and endothelium-dependent vasodilatation in men than in women. Conclusion. CHD is associated with significant sex differences in processes of lipid peroxidation - antioxidant protection, metabolism of nitric oxide, found, dilatation and anti-oxidation effect of atorvastatin.
Gender-specific changes in well-being in older people with coronary heart disease: evidence from the English Longitudinal Study of Ageing
